Skip to product information
1 of 1

Eg

Venoruton 500mg 30 coated tablets

Venoruton 500mg 30 coated tablets

Regular price €17,20
Regular price €18,10 Sale price €17,20
Sale Sold out
VAT included. Shipping calculated at checkout.
Logo Farmaci da banco

NET WEIGHT OF THE PRODUCT

30ct

EAN

017076148

MINSAN

017076148

View full details

In compliance with article 118 "authorization of advertising to the public" of the legislative decree of 24 April 2006, number 219

INDICATIONS

VENORUTON is indicated in the treatment of symptoms related to venous insufficiency; states of capillary fragility.

CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.

WARNINGS AND PRECAUTIONS FOR USE

Patients suffering from lower limb edema due to heart, kidney or liver disease should not take Venoruton as the effect of Venoruton is not proven in these indications. Pediatric population The use of Venoruton is not recommended in children. Venoruton gel: The use, especially if prolonged, of products to be applied to the skin can give rise to sensitization phenomena. In this case you should stop treatment and contact your doctor to institute suitable therapy. Important information about some excipients Venoruton 1000 mg powder contains: - sodium saccharin: this medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. Venoruton 500 mg film-coated tablets contain the azo coloring agent: - sunset yellow aluminum lake (E 110): may cause allergic reactions. Venoruton gel contains: - benzalkonium chloride: this medicinal product contains 0.391 mg of benzalkonium chloride per dose equivalent to 0.05 mg/g. Benzalkonium chloride may irritate the skin. If you are breastfeeding, do not apply this medicine to your breasts because your baby may ingest it with his milk.

INTERACTIONS

To date, no specific interaction of oxerutin with other medicinal products has been reported. In vitro data on a possible modulation of CYP3A activity by oxerutin components (quercetin and rutin present in trace amounts) are conflicting. Venoruton gel: no interactions with medicinal products have been reported.

SIDE EFFECTS

Venoruton oral formulations: Safety profile summary Venoruton may in rare cases cause gastrointestinal side effects or skin reactions such as gastrointestinal disorders, flatulence, diarrhoea, abdominal pain, stomach discomfort, dyspepsia, rash, itching or hives. Very rare is the appearance of dizziness, headache, hot flashes, tiredness or hypersensitivity reactions such as anaphylactoid reactions. Table of adverse reactions Side effects are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1,000); very rare (< 1/10,000), or not known (frequency cannot be estimated from the available data). Within each frequency class, undesirable effects are indicated in order of decreasing seriousness.

Classes Organ Systems / Frequency | Adverse reactions

Immune system disorders

Very rare | Adverse reactions: Anaphylactoid reactions

Very rare | Adverse reactions: Hypersensitivity reactions

Nervous system disorders

Very rare | Adverse reactions: Dizziness

Very rare | Adverse reactions: Headache

Vascular pathologies

Very rare | Adverse reactions: Hot flashes

Gastrointestinal disorders

Rare | Adverse reactions: Gastrointestinal disorders

Rare | Adverse reactions: Flatulence

Rare | Adverse reactions: Diarrhoea

Rare | Adverse reactions: Abdominal pain

Rare | Adverse reactions: Stomach problems

Rare | Adverse reactions: Dyspepsia

Pathologies of the skin and subcutaneous tissue

Rare | Adverse reactions: Rash

Rare | Adverse reactions: Itching

Rare | Adverse reactions: Urticaria

Systemic pathologies and conditions relating to the administration site

Very rare | Adverse reactions: Tiredness

Venoruton gel: Safety profile summary Venoruton gel is well tolerated. Rare cases of sensitization with the appearance of skin reactions have been observed. These symptoms disappear when treatment is stopped. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

  • ASSISTANCE - TELEPHONE ORDERS

    E-mail:
    help@dottortili.com


    WhatsApp:
    +39 3387296949


    Toll Free Number:
    800959222

  • SHIPPING

    Shipping to Italy 24/48H
    Delivery also on Saturday and Sunday
    Free over €49.90

    Shipping to Europe 24/72H
    Free over €80

  • SAFETY

    The security of your data is important to us!

    We strictly comply with the European GDPR regarding
    Privacy and processing of personal data

    The payments you make on our site are 100% safe and guaranteed

  • RETURNS

    For returns, contact our customer service: you have 14 days to change your mind.


    Immediate, free replacement of wrong or non-conforming products.

1 of 4

Responsibility for content
This sheet contains information that is not intended to replace a diagnosis or medical advice, as only a doctor can write any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.

Please note
The names of the products, the ingredients and the percentages indicated in the descriptions are purely indicative, they could be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting in real time to such updates, the photos and technical information of the products inserted on Dottortili.com may differ from those reported on the label or otherwise disseminated by the manufacturing companies. The only identification element is the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines all responsibility for any errors, omissions or failure to update the same. Dottortili.com does not assume responsibility for damages of any nature that may arise from access to the published information.

Data source: Farmadati Italia
Website: www.farmadati.it

The Farmadati Italia Database is used by almost all pharmacies, parapharmacies, herbalists, health shops, large-scale retail trade, computerized doctors, etc. thanks to the company's historical guarantee of reliability, seriousness and professionalism on the national territory.

The Farmadati Italia Srl management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO/IEC 27001:2017 for information security management systems.